Education
About Us
Working with TipRanks
Follow Us
ClearPoint Neuro (CLPT)
NASDAQ:CLPT
Top Page
ClearPoint Neuro
(NASDAQ:CLPT)
Rating:61Neutral
Price Target:
$13.00
▲( 7.62% Upside)
Positive Factors
Financial Health
The balance sheet is solid with over $20M of cash and no debt.
Growth
Functional Neuro growth in Q4 was strong at 43% year-over-year.
Partnerships
ClearPoint partners with accelerated development pathways cater to a patient population of over 2 million.
Negative Factors
Market Timing
The partner business recently had significant developments that accelerate $100s of millions of revenue opportunities, with 70%+ GMs, to being on the market as early as late 2026.
ClearPoint Neuro (CLPT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$361.51M
Dividend YieldN/A
Average Volume (3M)276.77K
Price to Earnings (P/E)―
Beta (1Y)1.42
Revenue Growth23.22%
EPS Growth9.54%
CountryUS
Employees115
SectorHealthcare
Sector Strength43
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.22
Shares Outstanding28,265,001
10 Day Avg. Volume355,930
30 Day Avg. Volume276,766
Financial Highlights & Ratios
PEG Ratio2.05
Price to Book (P/B)18.28
Price to Sales (P/S)0.00
P/FCF Ratio-31.73
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue2.98
Enterprise Value/Gross Profit18.43
Enterprise Value/Ebitda-5.09
Forecast
1Y Price Target
$27.67Price Target Upside129.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
ClearPoint Neuro Business Overview & Revenue Model
Company DescriptionClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
How the Company Makes MoneyClearPoint Neuro primarily generates revenue through the sale and leasing of its ClearPoint Neuro Navigation System, as well as disposable products associated with its use during surgical procedures. The company also earns income from service agreements and maintenance contracts related to their systems. Significant revenue streams include direct sales to hospitals and healthcare facilities, as well as partnerships and collaborations with medical device manufacturers and pharmaceutical companies that utilize ClearPoint's technology for drug delivery and other neurological applications. These partnerships often involve licensing agreements, which can provide additional revenue channels through royalties and milestone payments.
ClearPoint Neuro Financial Statement Overview
Summary
ClearPoint Neuro demonstrates positive revenue growth and a solid balance sheet with low leverage. However, the company faces challenges with profitability and sustaining positive operating cash flow. Continued focus on improving operational efficiency and profitability will be crucial for long-term success.Income Statement
ClearPoint Neuro has shown a consistent increase in revenue over the years, with a notable revenue growth rate of 31% from 2023 to 2024. However, the company continues to operate at a loss with a negative net profit margin of -60.3% in 2024. The gross profit margin remains strong at 60.9%, indicating efficient cost management relative to revenue. The EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.65
Positive
Balance Sheet
The company's balance sheet shows improvement in stockholders' equity, which increased to $25.4 million in 2024 from $21.2 million in 2023. The debt-to-equity ratio has improved significantly over the years, standing at 0.14 in 2024, indicating lower leverage risk. The equity ratio is robust at 64.8%, highlighting a strong capital structure. However, the company needs to address its negative net income for better return on equity.70
Positive
Cash Flow
ClearPoint Neuro's cash flow situation shows a positive trend in free cash flow growth, with free cash flow improving by 37.6% from 2023 to 2024. However, the operating cash flow remains negative, which could impact long-term sustainability. The company has been financing its operations through external funding, as seen in its financing cash flow.60
Neutral
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 32.24M | 31.39M | 23.95M | 20.55M | 16.30M | 12.83M | Gross Profit |
| 19.73M | 19.12M | 13.61M | 13.53M | 11.29M | 9.12M | EBIT |
| -21.68M | -19.75M | -22.45M | -16.33M | -13.37M | -6.22M | EBITDA |
| -20.25M | -17.84M | -20.99M | -15.58M | -12.74M | -4.79M | Net Income Common Stockholders |
| -20.79M | -18.91M | -22.09M | -16.54M | -15.32M | -9.11M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 12.39M | 20.10M | 23.14M | 37.49M | 54.11M | 20.10M | Total Assets |
| 30.07M | 39.19M | 42.66M | 55.49M | 65.58M | 29.64M | Total Debt |
| 3.44M | 3.57M | 13.94M | 11.99M | 12.28M | 24.24M | Net Debt |
| -8.95M | -16.54M | -9.20M | -15.63M | -41.83M | 4.14M | Total Liabilities |
| 10.08M | 13.80M | 21.49M | 18.60M | 16.79M | 27.26M | Stockholders Equity |
| 19.99M | 25.39M | 21.17M | 36.89M | 48.79M | 2.38M |
| Cash Flow | Free Cash Flow | ||||
| -11.74M | -9.22M | -14.77M | -17.31M | -12.87M | -8.29M | Operating Cash Flow |
| -11.28M | -8.95M | -13.72M | -16.17M | -12.70M | -7.81M | Investing Cash Flow |
| -458.00K | -275.00K | 8.95M | -10.74M | -168.00K | -482.00K | Financing Cash Flow |
| -11.23M | 6.19M | 296.00K | 409.00K | 46.88M | 22.69M |
ClearPoint Neuro Technical Analysis
Negative
12.08
Price Trends
12.90
Negative
14.56
Negative
13.40
Negative
Market Momentum
-0.18
Positive
41.44
Neutral
17.24
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLPT, the sentiment is Negative. The current price of 12.08 is below the 20-day moving average (MA) of 13.60, below the 50-day MA of 12.90, and below the 200-day MA of 13.40, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 41.44 is Neutral, neither overbought nor oversold. The STOCH value of 17.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLPT.
ClearPoint Neuro Risk Analysis
ClearPoint Neuro disclosed 49 risk factors in its most recent earnings report. ClearPoint Neuro reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ClearPoint Neuro Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $361.51M | ― | -76.21% | ― | 23.22% | 9.54% | |
60 Neutral | $241.78M | 14.87 | 8.12% | ― | 5.96% | -43.83% | |
57 Neutral | $586.11M | ― | -128.49% | ― | 22.05% | 29.86% | |
56 Neutral | $337.81M | ― | -7.46% | ― | -3.31% | -199.23% | |
53 Neutral | $5.14B | 3.06 | -43.57% | 2.81% | 16.81% | -0.12% | |
50 Neutral | $350.05M | ― | -30.11% | ― | 15.32% | 15.73% | |
42 Neutral | $306.09M | ― | -177.29% | ― | -23.99% | -100.40% |
* Healthcare Sector Average
Performance Comparison
CLPT
ClearPoint Neuro
12.08
5.87
94.52%
PACB
Pacific Biosciences
0.94
-1.00
-51.55%
TCMD
Tactile Systems Technology
9.81
-2.97
-23.24%
VREX
Varex Imaging
7.73
-6.95
-47.34%
NNOX
Nano-X Imaging
5.24
-3.35
-39.00%
NPCE
NeuroPace
17.87
10.27
135.13%
ClearPoint Neuro Earnings Call Summary
Earnings Call Date:May 13, 2025
(Q1-2025)
| % Change Since: -14.93%|
Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment Neutral
ClearPoint Neuro demonstrated solid revenue growth and expansion in its core segments, supported by successful capital funding. However, challenges remain with significant declines in capital equipment revenue and increased operating expenses. The company is investing in future growth, particularly in the biologics and drug delivery segment, but faces near-term financial pressures.Q1-2025 Updates
Positive Updates
Revenue Growth
Total revenue for Q1 2025 was $8.5 million, representing an 11% increase from Q1 2024's $7.6 million.
Biologics and Drug Delivery Revenue Increase
Revenue for biologics and drug delivery rose by 9% to $4.7 million in Q1 2025, fueled by a $1.2 million increase in product revenue.
Neurosurgery Navigation Revenue Surge
Neurosurgery navigation revenue increased by 70% to $3.3 million in Q1 2025, due to higher sales of new product offerings and an increased customer base.
Gross Margin Improvement
Gross margin for Q1 2025 was 60%, a 1% increase compared to 59% in Q1 2024.
Successful Capital Funding
ClearPoint Neuro secured foundational funding from Oberland Capital, providing flexibility with a new credit facility that includes $32 million net proceeds and potential for $25 million more.
Single Use Consumables Growth
Single use consumables business more than doubled with a 104% growth rate, driven by increased orders from biopharma partners and new product launches.
Negative Updates
Capital Equipment and Software Revenue Decline
Capital equipment and software revenue decreased by 63% to $0.5 million in Q1 2025, attributed to fewer new placements and timing of new product introductions.
Increased Operating Expenses
Research and development costs rose by 29%, sales and marketing expenses by 17%, and general and administrative expenses by 44% in Q1 2025, driven by higher personnel costs and professional service fees.
Cash and Cash Equivalents Reduction
Cash and cash equivalents totaled $12.4 million as of March 31, 2025, down from $20.1 million at December 31, 2024, due to increased operational cash burn.
Company Guidance
In the recent investor call, ClearPoint Neuro provided extensive guidance on their strategic focus and financial performance. The company reported a total revenue of $8.5 million for Q1 2025, marking an 11% increase from $7.6 million in Q1 2024. The biologics and drug delivery sector grew by 9% to $4.7 million, driven by a $1.2 million increase in product revenue, despite a $0.8 million decrease in services. The neurosurgery navigation segment saw a remarkable 70% growth to $3.3 million, attributed to new product offerings and an expanded customer base. Conversely, capital equipment and software revenue decreased by 63% to $0.5 million. The gross margin improved slightly to 60%, while research and development costs surged by 29% to $3.4 million. Sales and marketing expenses rose by 17% to $3.8 million, and general and administrative expenses increased by 44% to $4.1 million. The company also highlighted securing foundational funding from Oberland Capital, enhancing its financial flexibility with $32 million in net proceeds and access to an additional $25 million in credit. This financial strategy aims to support ClearPoint Neuro's ambitious growth initiatives and the anticipated commercialization of cell and gene therapies.ClearPoint Neuro Corporate Events
Executive/Board Changes
ClearPoint Neuro Updates Director Compensation Plan
Neutral
May 19, 2025
ClearPoint Neuro, Inc. has revised its Non-Employee Director Compensation Plan to attract and retain qualified board members by offering appropriate compensation. The updated plan, last revised on May 22, 2023, reflects the company’s commitment to strong corporate governance practices.
The most recent analyst rating on (CLPT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.
Private Placements and FinancingBusiness Operations and StrategyFinancial Disclosures
ClearPoint Neuro Reports Record Q1 2025 Revenue Growth
Positive
May 13, 2025
On May 13, 2025, ClearPoint Neuro reported its financial results for the first quarter of 2025, highlighting a record revenue of $8.5 million, marking an 11% increase from the previous year. The company experienced significant growth in its single-use navigation and therapy products, with a 70% increase in neurosurgery navigation and therapy revenue and a 104% rise in consumable product revenue. The FDA clearance of ClearPoint 3.0 Software contributed to this growth, enhancing operating room navigation and laser therapy capabilities. Despite capital market volatility, ClearPoint secured a long-term credit facility and equity investment, strengthening its financial position to achieve strategic objectives.
The most recent analyst rating on (CLPT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.
Private Placements and FinancingBusiness Operations and Strategy
ClearPoint Neuro Secures $110 Million Investment Deal
Positive
May 12, 2025
On May 12, 2025, ClearPoint Neuro announced a significant financial arrangement with Oberland Capital, securing up to $110 million in investment. This includes a $105 million note financing and a $3.5 million stock purchase, aimed at supporting the company’s growth in cell and gene therapy markets. The proceeds will be used for general corporate purposes, including capital expenditures and working capital. This partnership is expected to bolster ClearPoint Neuro’s ability to meet the demands of its pharmaceutical partners and expand its product offerings, thereby enhancing its market position in the medical technology industry.
The most recent analyst rating on (CLPT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.
Business Operations and StrategyFinancial Disclosures
ClearPoint Neuro Reports Record 2024 Revenue Growth
Positive
Feb 26, 2025
On February 26, 2025, ClearPoint Neuro announced its financial results for the fourth quarter and full year of 2024, highlighting a record revenue of $31.4 million for the year, marking a 31% increase over 2023. The company reduced its operational cash burn by 35% and activated 25 new global centers in 2024. ClearPoint Neuro aims to expand its global footprint and accelerate the launch of new products, focusing on supporting BioPharma partners in the commercialization of cell and gene therapies. The company anticipates revenue growth between 15% and 31% for 2025.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.